Shots:

• The US FDA’s VRBPAC voted 17 to 0 with 1 abstention in favor of recommending the EUA for COVID-19 vaccine in children aged 5 to <12yrs. with COVID-19
• The committee reviewed the P-II/III trial for the COVID-19 vaccine which showed a 90.7% vaccine efficacy in patients without prior SARS-CoV-2 infection @7 Days after 2nd dose- favorable safety profile & robust immune responses. Additionally- patients have received a two-dose regimen of 10-µg doses which was given 21 days apart while ⅓ of the 30-µg dose was used for patients aged 12yrs.
• If the US CDC’s ACIP grants EUA- Pfizer-BioNTech COVID-19 Vaccine will be the 1^st vaccine to be authorized in the US for use in patients aged 5 to <12yrs.

 ­ | Ref: Pfizer | Image: The Wall Street Journal